OSMF
MCID: ORL004
MIFTS: 55

Oral Submucous Fibrosis (OSMF)

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Oral Submucous Fibrosis

MalaCards integrated aliases for Oral Submucous Fibrosis:

Name: Oral Submucous Fibrosis 12 74 52 58 54 43 15 17 71 32
Oral Submucosal Fibrosis, Including of Tongue 12 71
Osmf 52 58
Oral Cavity Submucous Fibrosis 12
Oral Submucosal Fibrosis 12

Characteristics:

Orphanet epidemiological data:

58
oral submucous fibrosis
Age of onset: All ages;

Classifications:



External Ids:

Disease Ontology 12 DOID:5773
ICD9CM 34 528.8
MeSH 43 D009914
NCIt 49 C34866
SNOMED-CT 67 32883009
ICD10 32 K13.5
ICD10 via Orphanet 33 K13.5
UMLS via Orphanet 72 C0029172
Orphanet 58 ORPHA357154
UMLS 71 C0029171 C0029172

Summaries for Oral Submucous Fibrosis

NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 357154 Definition Oral submucous fibrosis (OSMF) is a chronic, progressive disease that alters the fibroelasticity of the oral submucosa, prevalent in India and Southeast Asia but rare elsewhere, and characterized by burning and pain in the oral cavity, loss of gustatory sensation, the presence of blanched fibrous bands and stiffening of the oral mucosa and oro-pharynx (leading to trismus and a progressive reduction in mouth opening) and an increased risk of developing oral squamous cell cancer (3-19%). It is usually associated with the chewing of the areca nut (an ingredient in betel quid) but the exact etiology is unknown and there is currently no effective treatment. Visit the Orphanet disease page for more resources.

MalaCards based summary : Oral Submucous Fibrosis, also known as oral submucosal fibrosis, including of tongue, is related to squamous cell carcinoma and oral cancer, and has symptoms including oral manifestations An important gene associated with Oral Submucous Fibrosis is LOX (Lysyl Oxidase), and among its related pathways/superpathways are ERK Signaling and Cytokine Signaling in Immune system. The drugs Hydrocortisone and Hyaluronic acid have been mentioned in the context of this disorder. Affiliated tissues include tongue, endothelial and salivary gland, and related phenotypes are narrow mouth and cheilitis

Wikipedia : 74 Oral submucous fibrosis is a chronic, complex, premalignant (1% transformation risk) condition of the... more...

Related Diseases for Oral Submucous Fibrosis

Diseases related to Oral Submucous Fibrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 299)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 30.7 TP53 PTGS2 MMP9 MMP2 CYP1A1 CDH1
2 oral cancer 30.7 TP53 PTGS2 MMP9 MMP2 GSTM1 CYP1A1
3 gingivitis 30.0 TNF TIMP1 MMP9
4 gastritis 29.9 TP53 TNF PTGS2 CDH1
5 tongue disease 29.8 TP53 MMP9 MMP2 CDH1
6 interstitial lung disease 29.7 TNF TIMP1 TGFB1 MMP9
7 localized scleroderma 29.7 TNF TGFB1 COL1A1
8 skin disease 29.3 TP53 TNF LOX LORICRIN ELN
9 periodontitis 29.3 TNF TIMP1 PTGS2 MMP9 MMP3 MMP2
10 fibrosis of extraocular muscles, congenital, 1 11.3
11 oral squamous cell carcinoma 11.0
12 leukoplakia 10.8
13 oral leukoplakia 10.8
14 lichen planus 10.5
15 leukoregulin 10.5 TGFB1 PTGS2
16 oral mucosa leukoplakia 10.5
17 iron metabolism disease 10.5
18 oral lichen planus 10.5
19 rheumatoid nodulosis 10.4 MMP9 MMP3
20 keratosis 10.4
21 prolapse of lacrimal gland 10.4 MMP9 MMP3
22 mid-dermal elastolysis 10.4 TIMP1 ELN
23 extracranial arteriovenous malformation 10.4 MMP9 MMP2
24 hypertrophic scars 10.4 TIMP1 TGFB1 MMP2
25 ureteric orifice cancer 10.4 LOX ELN
26 deficiency anemia 10.4
27 iron deficiency anemia 10.4
28 focal myositis 10.4 MMP9 MMP2
29 fibromatosis, gingival, 1 10.4 TGFB1 MMP2
30 vulvar intraepithelial neoplasia 10.4 TP53 CDH1
31 lentigo maligna melanoma 10.4 MMP9 MMP2
32 acute transverse myelitis 10.3 MMP9 MMP2
33 chronic actinic dermatitis 10.3 MMP9 ELN
34 verrucous carcinoma 10.3
35 posttransplant acute limbic encephalitis 10.3
36 sarcomatoid transitional cell carcinoma 10.3 TP53 CDH1
37 esophagus verrucous carcinoma 10.3 TP53 CDH1
38 adult teratoma 10.3 TP53 ENG
39 gastroschisis 10.3 MMP3 CYP1A1 CST3
40 fungal keratitis 10.3 TIMP1 MMP9
41 skin papilloma 10.3 TP53 PTGS2 LORICRIN
42 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.3
43 squamous cell papilloma 10.3
44 papilloma 10.3
45 cardia cancer 10.3 TP53 GSTM1 CYP1A1
46 spastic entropion 10.3 MMP9 MMP3 MMP2
47 cerebral aneurysms 10.3 MMP2 ELN CST3
48 chronic venous insufficiency 10.3 TIMP1 TGFB1 MMP9
49 nasal cavity squamous cell carcinoma 10.3 MMP9 MMP2
50 esophagus adenocarcinoma 10.3 TP53 PTGS2 CDH1

Graphical network of the top 20 diseases related to Oral Submucous Fibrosis:



Diseases related to Oral Submucous Fibrosis

Symptoms & Phenotypes for Oral Submucous Fibrosis

Human phenotypes related to Oral Submucous Fibrosis:

58 31 (show all 7)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 narrow mouth 58 31 hallmark (90%) Very frequent (99-80%) HP:0000160
2 cheilitis 58 31 hallmark (90%) Very frequent (99-80%) HP:0100825
3 abnormality of the pharynx 58 31 hallmark (90%) Very frequent (99-80%) HP:0000600
4 flexion contracture 58 31 frequent (33%) Frequent (79-30%) HP:0001371
5 trismus 58 31 frequent (33%) Frequent (79-30%) HP:0000211
6 oropharyngeal squamous cell carcinoma 58 31 occasional (7.5%) Occasional (29-5%) HP:0012182
7 abnormal oral cavity morphology 58 Very frequent (99-80%)

UMLS symptoms related to Oral Submucous Fibrosis:


oral manifestations

GenomeRNAi Phenotypes related to Oral Submucous Fibrosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CDH1 FLNA GSTM1 MMP2 PTGS2 TGFB1

MGI Mouse Phenotypes related to Oral Submucous Fibrosis:

45 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.37 CDH1 COL1A1 CST3 ENG FLNA LOX
2 homeostasis/metabolism MP:0005376 10.35 CDH1 COL1A1 CST3 CYP1A1 ENG FLNA
3 hematopoietic system MP:0005397 10.31 COL1A1 CYP1A1 ENG FLNA LOX MMP2
4 growth/size/body region MP:0005378 10.29 CDH1 COL1A1 CYP1A1 ENG FLNA MMP2
5 immune system MP:0005387 10.27 CDH1 COL1A1 CYP1A1 FLNA LOX MMP2
6 mortality/aging MP:0010768 10.25 CDH1 COL1A1 CST3 CYP1A1 ENG FLNA
7 digestive/alimentary MP:0005381 10.19 CDH1 COL1A1 ENG FLNA MMP9 PTGS2
8 endocrine/exocrine gland MP:0005379 10.18 CDH1 COL1A1 CST3 CYP1A1 PTGS2 TGFB1
9 craniofacial MP:0005382 10.09 COL1A1 ENG FLNA MMP2 TGFB1 TNF
10 integument MP:0010771 10.09 CDH1 COL1A1 ENG LOX MMP9 PTGS2
11 muscle MP:0005369 10.07 COL1A1 CST3 ENG LOX MMP2 MMP9
12 neoplasm MP:0002006 10.06 CDH1 COL1A1 CST3 LOX MMP2 MMP9
13 nervous system MP:0003631 10 COL1A1 CST3 ENG FLNA MMP2 MMP3
14 reproductive system MP:0005389 9.85 CDH1 COL1A1 CST3 FLNA MMP9 PTGS2
15 respiratory system MP:0005388 9.7 COL1A1 ENG FLNA LOX MMP2 MMP9
16 skeleton MP:0005390 9.36 COL1A1 FLNA LOX MMP2 MMP3 MMP9

Drugs & Therapeutics for Oral Submucous Fibrosis

Drugs for Oral Submucous Fibrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 43)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
2
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741
3
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
4 Anti-Inflammatory Agents Phase 3
5 Antioxidants Phase 3
6 Viscosupplements Phase 3
7 Adjuvants, Immunologic Phase 3
8 Hydrocortisone 17-butyrate 21-propionate Phase 3
9 Hydrocortisone hemisuccinate Phase 3
10 Immunologic Factors Phase 3
11
Curcumin Approved, Experimental, Investigational Phase 2 458-37-7 969516
12
tannic acid Approved Phase 2 1401-55-4
13
Benzocaine Approved, Investigational Phase 2 94-09-7, 1994-09-7 2337
14
leucovorin Approved Phase 2 58-05-9 6006 143
15
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
16
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
17
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
18 Analgesics, Non-Narcotic Phase 2
19 Analgesics Phase 2
20 Antirheumatic Agents Phase 2
21 Anti-Inflammatory Agents, Non-Steroidal Phase 2
22 Protective Agents Phase 2
23 Micronutrients Phase 2
24 Trace Elements Phase 2
25 Vitamins Phase 2
26 Antidotes Phase 2
27 Vitamin B Complex Phase 2
28 Folate Phase 2
29 Nutrients Phase 2
30 Astragalus Phase 2
31 Antimetabolites Phase 2
32 Vitamin B9 Phase 2
33
Heparin Approved, Investigational 9005-49-6 46507594 772
34
Ethanol Approved 64-17-5 702
35
Lobeline Investigational 90-69-7
36 Antibodies
37 Autoantibodies
38 Immunoglobulins
39 Hemostatics
40 Tolonium Chloride
41 calcium heparin
42 Coagulants
43 Pharmaceutical Solutions

Interventional clinical trials:

(show all 14)
# Name Status NCT ID Phase Drugs
1 Comparing the Test Characteristics of Three Oral Cancer Screening Techniques:1)Unaided Visual Examination 2)VelScope Examination and 3)Toluidine Blue Application, by Trained Primary Health Care Workers in Mumbai, India. Unknown status NCT00655421 Phase 3
2 Evaluation of Efficacy of Aloevera in the Treatment of Oral Submucous Fibrosis- A Clinical Study Completed NCT02714543 Phase 3 aloevera juice;Hydrocortisone;Hyaluronic Acid;antioxidant;aloevera gel
3 Topical Application of Curcumin Incorporated in Orabase in OSMF Patients Unknown status NCT02645656 Phase 2 Curcumin Arm
4 Innovative Formulations of Curcumin & Its Comparative Efficacy in Management of Oral Submucous Fibrosis. Unknown status NCT03511261 Phase 2 10% Curcumin mucoadhesive gel;Curcumin capsules 500mg;5% curcumin mucoadhesive gel + Curcumin capsules 250 mg;Placebo capsule
5 A Phase II Double-blind and Randomized Trial Comparing Concurrent Chemoradiotherapy Plus PG2 Injection Versus Concurrent Chemoradiotherapy Plus Placebo in Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Terminated NCT01720563 Phase 2 Astragalus polysaccharides 500 mg;Placebo
6 Interventional Study to Determine the Effectiveness of Medium Intensity Verses Low Intensity Tobacco Use Prevention and Cessation Intervention in the Unorganized Sector of Zari Workers in Mumbai Unknown status NCT02103868
7 Evaluation of Auto Antibodies in Oral Sub Mucous Fibrosis - a Clinico-pathological Study Completed NCT03011086
8 Evaluation of Change in Mouth Opening in Oral Submucous Fibrosis Patients After Surgical Excision of Fibrous Bands Along With Bilateral Coronoidotomy and Surgical Defect Coverage by Single Stage Extended Nasolabial Flap Completed NCT02711046
9 Risk Assessment of Malignant Transformation in Oral Submucous Fibrosis Using Epithelial Mesenchymal Transition (EMT) Signatures in Tissue Samples and Saliva Completed NCT03732872
10 Development of an Oral Epithelial Dysplasia Informational Needs Questionnaire Completed NCT04153266
11 Impact of 'Gutkha and Pan Masala Ban' in the State of Maharashtra on Users and Vendors Completed NCT01896375
12 Efficacy of Rose Bengal in Comparison With Toluidine Blue in Detection of Premalignant Lesions: a Preliminary Study Completed NCT03031899
13 Evaluation of Functional Dimensions of Macintosh Blade During Laryngoscopy in Patients With Normal Mouth Opening: Development of a Feasibility Model for Facilitation of Laryngoscopy in Cases of Mouth Opening Restriction Due to Submucous Fibrosis Recruiting NCT02639897
14 Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions Not yet recruiting NCT03682562

Search NIH Clinical Center for Oral Submucous Fibrosis

Cochrane evidence based reviews: oral submucous fibrosis

Genetic Tests for Oral Submucous Fibrosis

Anatomical Context for Oral Submucous Fibrosis

MalaCards organs/tissues related to Oral Submucous Fibrosis:

40
Tongue, Endothelial, Salivary Gland, Skin, Testes, Smooth Muscle, T Cells

Publications for Oral Submucous Fibrosis

Articles related to Oral Submucous Fibrosis:

(show top 50) (show all 1258)
# Title Authors PMID Year
1
Association between lysyl oxidase polymorphisms and oral submucous fibrosis in older male areca chewers. 54 61
18764858 2009
2
Expression of matrix metalloproteinases (MMP-1, MMP-2 and MMP-9) and their inhibitors (TIMP-1 and TIMP-2) in oral submucous fibrosis. 54 61
17217211 2006
3
Augmented mRNA expression of tissue inhibitor of metalloproteinase-1 in buccal mucosal fibroblasts by arecoline and safrole as a possible pathogenesis for oral submucous fibrosis. 54 61
12907213 2003
4
The upregulation of lysyl oxidase in oral submucous fibrosis and squamous cell carcinoma. 54 61
10426196 1999
5
Increased lysyl oxidase activity in fibroblasts cultured from oral submucous fibrosis associated with betel nut chewing in Taiwan. 54 61
8537914 1995
6
Expression of hTERT in Oral Submucous Fibrosis and Oral Squamous Cell Carcinoma - an Immunohistochemical Analysis. 61
31489575 2020
7
Treatment outcomes of laser therapy in oral submucous fibrosis-a systematic review. 61
32509514 2020
8
Impact of Oral Submucous Fibrosis on Quality of Life: A Multifactorial Assessment. 61
32346236 2020
9
Positive Feedback Loop of SNAIL-IL-6 Mediates Myofibroblastic Differentiation Activity in Precancerous Oral Submucous Fibrosis. 61
32570756 2020
10
Turmeric in the management of oral submucous fibrosis - A systematic review and meta-analysis. 61
32536848 2020
11
Photobiomodulation therapy inhibits oral submucous fibrosis in mice. 61
32391600 2020
12
Oral submucous fibrosis and COVID-19: Perspective on comorbidity. 61
32505551 2020
13
Comparative Evaluation of Mitochondrial Antioxidants in Oral Potentially Malignant Disorders. 61
32378537 2020
14
DNA content abnormality in oral submucous fibrosis concomitant leukoplakia: A preliminary evaluation of the diagnostic and clinical implications. 61
32433822 2020
15
Inhibition of HIF1A-AS1 impedes the arecoline-induced migration activity of human oral mucosal fibroblasts. 61
31959495 2020
16
No age predilection for a disease like OSMF. A case report of 5-year-old child. 61
32346505 2020
17
Histo-Blood Group Antigens in Oral Cancer and Potentially Malignant Disorders. 61
32334486 2020
18
The use of Velscope to assess cellular changes occuring in oral premalignancy. 61
32211285 2020
19
Study on the expression and function of smad family member 7 in oral submucous fibrosis and oral squamous cell carcinoma. 61
32114253 2020
20
Evaluation and Expression of Survivin in Potentially Malignant Lesions and Squamous Cell Carcinoma: A Comparative Study. 61
32382455 2020
21
In vitro Quantification of Collagen and Snail1 Gene Expression in Experimentally Induced Fibrosis by Arecoline and Commercial Smokeless Tobacco Products. 61
32334483 2020
22
Expression of transforming growth factor beta in oral submucous fibrosis. 61
32489816 2020
23
LINC00312/YBX1 Axis Regulates Myofibroblast Activities in Oral Submucous Fibrosis. 61
32340273 2020
24
Oral submucous fibrosis in Asian countries. 61
31310693 2020
25
Appearance of a primary in a case of 'carcinoma unkown primary' with advanced oral submucous fibrosis. 61
32305311 2020
26
Expression of Salivary S100A7 Levels in Stage I Oral Submucous Fibrosis: A Clinical and Laboratory Study. 61
32334479 2020
27
Network-based identification of signature genes KLF6 and SPOCK1 associated with oral submucous fibrosis. 61
32190310 2020
28
Proliferative ability and accumulation of cancer stem cells in oral submucous fibrosis epithelium. 61
32267986 2020
29
miR-10b regulated by Twist maintains myofibroblasts activities in oral submucous fibrosis. 61
32265096 2020
30
Role of the arecoline/YAP1/BMP4 pathway in promoting endothelial-mesenchymal transition in oral submucous fibrosis. 61
31397922 2020
31
Assessment of Eustachian tube functioning following surgical intervention of Oral Submucus Fibrosis by using tympanometry & audiometry. 61
32489829 2020
32
Efficacy of hyaluronidase combined with corticosteroids in treatment of oral submucous fibrosis: A meta-analysis of randomized controlled clinical trials. 61
32145110 2020
33
Patterns of Tobacco Use and its Relation to Oral Precancers and Cancers among Individuals Visiting a Tertiary Hospital in South India. 61
32434979 2020
34
Role of autophagy and apoptosis in atrophic epithelium in oral submucous fibrosis. 61
32132327 2020
35
Human papillomavirus prevalence in oral potentially malignant disorders: Systematic review and meta-analysis. 61
32144837 2020
36
Potentially malignant disorders of the oral cavity and oral dysplasia: A systematic review and meta-analysis of malignant transformation rate by subtype. 61
31803979 2020
37
Cytokines secreted by arecoline activate fibroblasts that affect the balance of TH17 and Treg. 61
31610043 2020
38
E3 ligase carboxyl-terminus of Hsp70-interacting protein (CHIP) suppresses fibrotic properties in oral mucosa. 61
31653576 2020
39
Prevalence of oral premalignant lesions and conditions among the population of Kanpur City, India: A cross-sectional study. 61
32318471 2020
40
Comparative Evaluation of SMAD-2 Expression in Oral Submucous Fibrosis and Reactive Oral Lesions. 61
32102517 2020
41
A systematic review on the mechanisms of malignant transformation of oral submucous fibrosis. 61
32039930 2020
42
ANDB: Development of a Database Based on a Global Survey of Literature on Areca Nut and Associated Health Effects. 61
31347432 2020
43
Malignant development in patients with oral potentially malignant disorders detected through nationwide screening: Outcomes of 5-year follow-up at a single hospital. 61
31589002 2020
44
CD1a+ and CD207+ cells are reduced in oral submucous fibrosis and oral squamous cell carcinoma. 61
31880289 2020
45
Expression of salivary miRNA 21 in Oral Submucous Fibrosis (OSMF): An observational study. 61
31985389 2020
46
Second field tumors in oral submucous fibrosis: An abandoned phenomenon? 61
31629662 2020
47
Study of Hypoxia-inducible factor-2α expression in the malignant transformation of Oral submucous fibrosis. 61
32508445 2020
48
Malignant potentiality assessment of oral submucous fibrosis through semi-quantitative approach. 61
32508480 2020
49
Letter to the Editor: "YAP-Induced Endothelial-Mesenchymal Transition in Oral Submucous Fibrosis". 61
31725341 2020
50
Response to the Letter to the Editor: "YAP-Induced Endothelial-Mesenchymal Transition in Oral Submucous Fibrosis". 61
31725356 2020

Variations for Oral Submucous Fibrosis

Cosmic variations for Oral Submucous Fibrosis:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM120376601 upper aerodigestive tract,mouth,other,premalignant c.85C>T p.R29* 9:21971121-21971121 0

Expression for Oral Submucous Fibrosis

Search GEO for disease gene expression data for Oral Submucous Fibrosis.

Pathways for Oral Submucous Fibrosis

Pathways related to Oral Submucous Fibrosis according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.78 TP53 TNF TIMP1 TGFB1 PTGS2 FLNA
2
Show member pathways
13.29 TP53 TNF TIMP1 TGFB1 PTGS2 MMP9
3
Show member pathways
12.79 MMP9 MMP3 LOX ELN COL1A1
4 12.79 TP53 TGFB1 PTGS2 MMP9 MMP2 GSTM1
5
Show member pathways
12.56 TIMP1 TGFB1 MMP9 MMP3 MMP2 LOX
6
Show member pathways
12.28 TNF PTGS2 MMP9 MMP3
7
Show member pathways
12.26 TP53 TIMP1 MMP3 COL1A1
8 12.22 TP53 TNF TGFB1 MMP9 MMP2 FLNA
9 12.08 TP53 TNF TGFB1 PTGS2 MMP9 MMP2
10 12.05 TP53 TNF MMP9 MMP2 GSTM1
11 11.98 MMP9 MMP3 MMP2 COL1A1 CDH1
12 11.95 TP53 TNF TGFB1 PTGS2 MMP9
13 11.92 TNF PTGS2 MMP9 MMP3
14 11.86 TNF TGFB1 MMP2 COL1A1
15
Show member pathways
11.85 TNF TIMP1 MMP9 MMP3 MMP2
16 11.74 MMP9 MMP2 CDH1
17 11.7 TNF TGFB1 CDH1
18 11.7 TP53 MMP9 MMP2 CDH1
19
Show member pathways
11.69 TGFB1 LOX ELN
20 11.67 TP53 TGFB1 MMP2 FLNA
21
Show member pathways
11.63 TNF PTGS2 MMP9 MMP3 MMP2
22 11.59 TIMP1 MMP9 MMP3 MMP2 COL1A1
23 11.58 TNF TGFB1 ENG
24 11.51 TP53 TNF MMP2
25 11.51 TP53 TGFB1 PTGS2
26 11.48 TNF TIMP1 PTGS2
27 11.47 TNF TGFB1 CYP1A1
28 11.46 TNF PTGS2 CYP1A1
29 11.46 TNF MMP9 MMP2
30 11.45 TIMP1 TGFB1 PTGS2 MMP9 MMP3 MMP2
31 11.43 TNF TIMP1 TGFB1 MMP9 MMP2 ELN
32 11.36 MMP9 MMP3 ELN
33 11.28 TP53 TNF TIMP1 TGFB1 PTGS2 MMP9
34 11.09 MMP9 MMP2 CST3
35 10.96 TNF TIMP1 TGFB1 ELN COL1A1 CDH1

GO Terms for Oral Submucous Fibrosis

Cellular components related to Oral Submucous Fibrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.85 TNF TIMP1 TGFB1 MMP9 MMP3 MMP2
2 extracellular region GO:0005576 9.73 TNF TIMP1 TGFB1 MMP9 MMP3 MMP2
3 collagen-containing extracellular matrix GO:0062023 9.65 TGFB1 MMP9 MMP2 ELN COL1A1
4 extracellular matrix GO:0031012 9.23 TIMP1 TGFB1 MMP9 MMP3 MMP2 LOX

Biological processes related to Oral Submucous Fibrosis according to GeneCards Suite gene sharing:

(show all 47)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 10.03 TP53 TNF TGFB1 PTGS2 MMP9
2 heart development GO:0007507 10 TP53 TGFB1 LOX ENG
3 regulation of cell proliferation GO:0042127 9.99 TP53 TNF TGFB1 PTGS2
4 positive regulation of protein phosphorylation GO:0001934 9.97 TNF TGFB1 MMP9 ENG
5 aging GO:0007568 9.96 TIMP1 TGFB1 PTGS2 CYP1A1
6 response to hypoxia GO:0001666 9.94 TGFB1 MMP2 CYP1A1 CST3
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.88 TNF TGFB1 PTGS2
8 response to organic cyclic compound GO:0014070 9.87 TGFB1 PTGS2 CYP1A1 CST3
9 cellular response to organic cyclic compound GO:0071407 9.86 TNF TGFB1 CYP1A1
10 positive regulation of smooth muscle cell proliferation GO:0048661 9.85 TNF PTGS2 MMP2
11 response to estradiol GO:0032355 9.85 TGFB1 PTGS2 CST3 COL1A1
12 cellular response to amino acid stimulus GO:0071230 9.84 TNF MMP2 COL1A1
13 positive regulation of protein complex assembly GO:0031334 9.83 TNF TGFB1 MMP3
14 wound healing GO:0042060 9.83 TIMP1 TGFB1 LOX COL1A1
15 cellular response to mechanical stimulus GO:0071260 9.81 TGFB1 PTGS2 ENG COL1A1
16 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.8 TNF MMP9 MMP2
17 extracellular matrix disassembly GO:0022617 9.78 TIMP1 MMP9 MMP3 MMP2
18 collagen catabolic process GO:0030574 9.77 MMP9 MMP3 MMP2
19 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.77 TP53 TNF TGFB1
20 protein kinase B signaling GO:0043491 9.76 TNF TGFB1 LOX
21 cytokine-mediated signaling pathway GO:0019221 9.76 TP53 TNF TIMP1 TGFB1 PTGS2 MMP9
22 negative regulation of mitotic cell cycle GO:0045930 9.75 TP53 TNF TGFB1
23 face morphogenesis GO:0060325 9.73 TGFB1 MMP2 COL1A1
24 response to organic substance GO:0010033 9.73 TNF TIMP1 TGFB1 PTGS2 CYP1A1 CDH1
25 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 9.71 TGFB1 LOX ENG
26 positive regulation of histone deacetylation GO:0031065 9.7 TP53 TGFB1
27 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.69 TP53 TGFB1
28 response to salt stress GO:0009651 9.69 TP53 TNF
29 bone trabecula formation GO:0060346 9.68 MMP2 COL1A1
30 negative regulation of neuroblast proliferation GO:0007406 9.68 TP53 TGFB1
31 response to corticosteroid GO:0031960 9.67 ENG COL1A1
32 regulation of striated muscle tissue development GO:0016202 9.67 TGFB1 LOX
33 response to amyloid-beta GO:1904645 9.67 MMP9 MMP3 MMP2
34 embryo implantation GO:0007566 9.67 PTGS2 MMP9 MMP2 CST3
35 positive regulation of mononuclear cell migration GO:0071677 9.65 TNF TGFB1
36 regulation of tissue remodeling GO:0034103 9.65 TP53 CST3
37 intramembranous ossification GO:0001957 9.64 MMP2 COL1A1
38 cell activation GO:0001775 9.63 TIMP1 TGFB1 CST3
39 connective tissue development GO:0061448 9.62 TGFB1 LOX
40 positive regulation of fever generation GO:0031622 9.62 TNF PTGS2
41 positive regulation of protein import into nucleus GO:0042307 9.62 TGFB1 PTGS2 FLNA CDH1
42 negative regulation of extracellular matrix disassembly GO:0010716 9.61 TGFB1 CST3
43 connective tissue replacement involved in inflammatory response wound healing GO:0002248 9.61 TIMP1 TGFB1
44 regulation of neuroinflammatory response GO:0150077 9.61 PTGS2 MMP9 MMP3
45 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.58 TP53 TNF TGFB1
46 extracellular matrix organization GO:0030198 9.56 TNF MMP9 MMP3 MMP2 LOX ELN
47 response to drug GO:0042493 9.28 TP53 TGFB1 PTGS2 LOX ENG CYP1A1

Molecular functions related to Oral Submucous Fibrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.21 TP53 TNF TIMP1 TGFB1 PTGS2 MMP9
2 identical protein binding GO:0042802 9.56 TP53 TNF TGFB1 MMP9 ENG CST3
3 enzyme binding GO:0019899 9.55 TP53 TGFB1 PTGS2 GSTM1 CYP1A1
4 type I transforming growth factor beta receptor binding GO:0034713 9.37 TGFB1 ENG
5 type II transforming growth factor beta receptor binding GO:0005114 9.32 TGFB1 ENG
6 protease binding GO:0002020 9.02 TP53 TNF TIMP1 CST3 COL1A1

Sources for Oral Submucous Fibrosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....